DPP

亜型選択性的な製品

シグナル伝達経路

DPPシグナル伝達経路

DPP製品

  • All (14)
  • DPP阻害剤 (14)
  • 新製品
製品コード 製品名称 製品説明 文献中Selleckの製品使用例 お客様のフィードバック
S5079 Sitagliptin Sitagliptin (MK-0431) is an oral and highly selective DPP-4 inhibitor with an IC50 of 18 nM. It is used for the treatment of type 2 diabetes.
OPARU, 2024, 10.18725/OPARU-52005
Mol Biotechnol, 2023, 10.1007/s12033-023-00992-9
bioRxiv, 2023, 10.1101/2023.12.18.572126
S3033 Vildagliptin Vildagliptin inhibits DPP−4 with IC50 of 2.3 nM.
J Clin Invest, 2023, 133(12)e165933
Oncoimmunology, 2023, 12(1):2268257
J Clin Med, 2023, 12(14)4632
S4002 Sitagliptin phosphate monohydrate Sitagliptin phosphate monohydrate (MK-0431) is a potent inhibitor of DPP-IV with IC50 of 19 nM in Caco-2 cell extracts.
Front Oncol, 2021, 11:704024
J Biomol Struct Dyn, 2021, 1-12
J Diabetes Res, 2020, 2020:2450781
S1540 Saxagliptin (BMS-477118) Saxagliptin (BMS-477118, Onglyza) is a selective and reversible DPP4 inhibitor with IC50 of 26 nM.
Turk J Pharm Sci, 2019, 16(2):227-233
Cancer Cell, 2018, 34(4):659-673
J Chromatogr B Analyt Technol Biomed Life Sci, 2018, 1083:249-257
S8455 Talabostat (PT-100) Talabostat (Val-boroPro, PT-100) is a dipeptidyl peptidase inhibitor with IC50 values of <4 nM, 4 nM, 11 nM, 310 nM, 560 nM and 390 nM for DPP-IV, DPP8, DPP9, QPP, FAP and PEP respectively. It has antineoplastic and hematopoiesis- stimulating activities.
Nat Chem Biol, 2023, 19(4):431-439
Cancer Gene Ther, 2023, 30(4):608-621
Acta Pharm Sin B, 2022, 12(3):1288-1304
S9631 Puromycin aminonucleoside Puromycin aminonucleoside (NSC 3056, PAN, Stylomycin aminonucleoside, ARDMA, SAN), the aminonucleoside portion of the antibiotic puromycin, is a reversible inhibitor of dipeptidyl-peptidase II and cytosol alanyl aminopeptidase that induces apoptosis in mesangial cells (MCs) accompanied by declined cell viability and enhanced inflammatory response.
Cell Mol Biol Lett, 2023, 28(1):62
Cell Mol Biol Lett, 2023, 28(1):62
Oral Dis, 2022, 10.1111/odi.14321
S8565 Omarigliptin (MK-3102) Omarigliptin (MK-3102) is a competitive, reversible inhibitor of DPP-4 (IC50 = 1.6 nM, Ki = 0.8 nM). It is highly selective over all proteases tested (IC50 > 67 μM), including QPP, FAP, PEP, DPP8, and DPP9 and has weak ion channel activity (IC50 > 30 μM at IKr, Caγ1.2, and Naγ1.5).
Acta Pharmacol Sin, 2021, 1-9
Front Behav Neurosci, 2021, 15:705579
S2868 Alogliptin (SYR-322) benzoate Alogliptin (SYR-322) benzoate is a potent, selective inhibitor of DPP-4 with IC50 of <10 nM, exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9.
Cell Rep, 2017, 20(7):1692-1704
S5365 Alogliptin Alogliptin is a potent, selective inhibitor of the serine protease dipeptidyl peptidase IV (DPP-4)with IC50 values of 2.63 nM and exhibits greater than 10,000 fold selectivity over the closely related serine proteases DPP-8 and DPP-9.
Sci Adv, 2021, 7(27)eabh3032
S4697 Saxagliptin hydrate Saxagliptin H2O (BMS-477118, Onglyza) is a selective and reversible DPP4 inhibitor with IC50 of 26 nM.
Turk J Pharm Sci, 2019, 16(2):227-233
S5909 Anagliptin Anagliptin is an orally active and highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor and exerts anti-inflammatory effects on macrophages, adipocytes, and mouse livers by suppressing NF-κB activation.
S7513 Trelagliptin Trelagliptin (SYR-472), a potent, orally active and highly selective DPP-4 inhibitor with an IC50 of 4 nM, improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM).
S5063 Trelagliptin succinate Trelagliptin succinate (SYR472) is a dipeptidyl peptidase IV (DPP-4) inhibitor which is used as a new long-acting drug for once-weekly treatment of type 2 diabetes mellitus (DM).
E0122 Gemigliptin Gemigliptin (Zemiglo, LC15-0444) is a potent, selective and long-acting dipeptidyl peptidase 4 (DPP 4) inhibitor with a Ki of 7.25 nM. Gemigliptin shows at least >23,000-fold selectivity for DPP-4 over various proteases and peptidases, including DPP-8, DPP-9, and fibroblast activation protein (FAP)-α.
S5079 Sitagliptin Sitagliptin (MK-0431) is an oral and highly selective DPP-4 inhibitor with an IC50 of 18 nM. It is used for the treatment of type 2 diabetes.
OPARU, 2024, 10.18725/OPARU-52005
Mol Biotechnol, 2023, 10.1007/s12033-023-00992-9
bioRxiv, 2023, 10.1101/2023.12.18.572126
S3033 Vildagliptin Vildagliptin inhibits DPP−4 with IC50 of 2.3 nM.
J Clin Invest, 2023, 133(12)e165933
Oncoimmunology, 2023, 12(1):2268257
J Clin Med, 2023, 12(14)4632
S4002 Sitagliptin phosphate monohydrate Sitagliptin phosphate monohydrate (MK-0431) is a potent inhibitor of DPP-IV with IC50 of 19 nM in Caco-2 cell extracts.
Front Oncol, 2021, 11:704024
J Biomol Struct Dyn, 2021, 1-12
J Diabetes Res, 2020, 2020:2450781
S1540 Saxagliptin (BMS-477118) Saxagliptin (BMS-477118, Onglyza) is a selective and reversible DPP4 inhibitor with IC50 of 26 nM.
Turk J Pharm Sci, 2019, 16(2):227-233
Cancer Cell, 2018, 34(4):659-673
J Chromatogr B Analyt Technol Biomed Life Sci, 2018, 1083:249-257
S8455 Talabostat (PT-100) Talabostat (Val-boroPro, PT-100) is a dipeptidyl peptidase inhibitor with IC50 values of <4 nM, 4 nM, 11 nM, 310 nM, 560 nM and 390 nM for DPP-IV, DPP8, DPP9, QPP, FAP and PEP respectively. It has antineoplastic and hematopoiesis- stimulating activities.
Nat Chem Biol, 2023, 19(4):431-439
Cancer Gene Ther, 2023, 30(4):608-621
Acta Pharm Sin B, 2022, 12(3):1288-1304
S9631 Puromycin aminonucleoside Puromycin aminonucleoside (NSC 3056, PAN, Stylomycin aminonucleoside, ARDMA, SAN), the aminonucleoside portion of the antibiotic puromycin, is a reversible inhibitor of dipeptidyl-peptidase II and cytosol alanyl aminopeptidase that induces apoptosis in mesangial cells (MCs) accompanied by declined cell viability and enhanced inflammatory response.
Cell Mol Biol Lett, 2023, 28(1):62
Cell Mol Biol Lett, 2023, 28(1):62
Oral Dis, 2022, 10.1111/odi.14321
S8565 Omarigliptin (MK-3102) Omarigliptin (MK-3102) is a competitive, reversible inhibitor of DPP-4 (IC50 = 1.6 nM, Ki = 0.8 nM). It is highly selective over all proteases tested (IC50 > 67 μM), including QPP, FAP, PEP, DPP8, and DPP9 and has weak ion channel activity (IC50 > 30 μM at IKr, Caγ1.2, and Naγ1.5).
Acta Pharmacol Sin, 2021, 1-9
Front Behav Neurosci, 2021, 15:705579
S2868 Alogliptin (SYR-322) benzoate Alogliptin (SYR-322) benzoate is a potent, selective inhibitor of DPP-4 with IC50 of <10 nM, exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9.
Cell Rep, 2017, 20(7):1692-1704
S5365 Alogliptin Alogliptin is a potent, selective inhibitor of the serine protease dipeptidyl peptidase IV (DPP-4)with IC50 values of 2.63 nM and exhibits greater than 10,000 fold selectivity over the closely related serine proteases DPP-8 and DPP-9.
Sci Adv, 2021, 7(27)eabh3032
S4697 Saxagliptin hydrate Saxagliptin H2O (BMS-477118, Onglyza) is a selective and reversible DPP4 inhibitor with IC50 of 26 nM.
Turk J Pharm Sci, 2019, 16(2):227-233
S5909 Anagliptin Anagliptin is an orally active and highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor and exerts anti-inflammatory effects on macrophages, adipocytes, and mouse livers by suppressing NF-κB activation.
S7513 Trelagliptin Trelagliptin (SYR-472), a potent, orally active and highly selective DPP-4 inhibitor with an IC50 of 4 nM, improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM).
S5063 Trelagliptin succinate Trelagliptin succinate (SYR472) is a dipeptidyl peptidase IV (DPP-4) inhibitor which is used as a new long-acting drug for once-weekly treatment of type 2 diabetes mellitus (DM).
E0122 Gemigliptin Gemigliptin (Zemiglo, LC15-0444) is a potent, selective and long-acting dipeptidyl peptidase 4 (DPP 4) inhibitor with a Ki of 7.25 nM. Gemigliptin shows at least >23,000-fold selectivity for DPP-4 over various proteases and peptidases, including DPP-8, DPP-9, and fibroblast activation protein (FAP)-α.

DPP阻害剤の選択性比較

Tags: DPP inhibitor|DPP agonist|DPP activator|DPP inducer|DPP antagonist|DPP signaling pathway|DPP assay kit